Volume 82, Issue 12, Pages (December 2012)

Slides:



Advertisements
Similar presentations
Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Long-term Risk of Mortality and End-Stage Renal Disease.
Advertisements

Date of download: 6/25/2016 From: Blood Pressure and Mortality in U.S. Veterans With Chronic Kidney Disease: A Cohort Study Ann Intern Med. 2013;159(4):
Date of download: 7/3/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Fibroblast Growth Factor 23 and Risks of Mortality.
Copyright © 2014 American Medical Association. All rights reserved.
Urine Potassium Excretion, Kidney Failure, and Mortality in CKD
Vitamin D levels and patient outcome in chronic kidney disease
Optimization of pre-ESRD care: The key to improved dialysis outcomes
Chronic Kidney Disease in Diabetes
Volume 81, Issue 5, Pages (March 2012)
Nutrition and chronic kidney disease
Beta blockers in the management of chronic kidney disease
Thyroid Status and Death Risk in US Veterans With Chronic Kidney Disease  Connie M. Rhee, MD, MSc, Kamyar Kalantar-Zadeh, MD, MPH, PhD, Vanessa Ravel,
Chapter 2: Pharmacological cholesterol-lowering treatment in adults
Volume 150, Issue 4, Pages e1 (April 2016)
Thinking Beyond New Clinical Guidelines: Update in Hypertension
Volume 93, Issue 4, Pages (April 2018)
Survival differences between peritoneal dialysis and hemodialysis among “large” ESRD patients in the United States  Austin G. Stack, Bhamidipati V.R.
Gudrun Hatlen, Solfrid Romundstad, Stein I. Hallan 
Corrections to "Estimating the glomerular filtration rate from serum creatinine is better than from cystatin C for evaluating risk factors associated.
Volume 80, Issue 1, Pages (July 2011)
Volume 64, Issue 3, Pages (September 2003)
Impact of Electronic Acute Kidney Injury (AKI) Alerts With Automated Nephrologist Consultation on Detection and Severity of AKI: A Quality Improvement.
Type of vascular access and mortality in U.S. hemodialysis patients
Volume 80, Issue 2, Pages (July 2011)
Volume 82, Issue 12, Pages (December 2012)
Volume 86, Issue 4, Pages (October 2014)
Molly E. Waring, PhD, Jane S
Volume 79, Pages S9-S13 (April 2011)
Volume 79, Issue 12, Pages (June 2011)
Steven G. Coca, Swathi Singanamala, Chirag R. Parikh 
Volume 76, Issue 10, Pages (November 2009)
Volume 84, Issue 5, Pages (November 2013)
Volume 84, Issue 1, Pages (July 2013)
Steven J. Rosansky, Richard J. Glassock  Kidney International 
Nutrition and chronic kidney disease
Volume 82, Issue 3, Pages (August 2012)
Volume 77, Issue 7, Pages (April 2010)
Volume 79, Issue 9, Pages (May 2011)
Stephen P. McDonald  Kidney International Supplements 
Volume 85, Issue 6, Pages (June 2014)
Jennifer E. Flythe, Stephen E. Kimmel, Steven M. Brunelli 
U-shaped effect of eGFR and mortality
Volume 76, Issue 6, Pages (September 2009)
Volume 83, Issue 4, Pages (April 2013)
Volume 81, Issue 5, Pages (March 2012)
Volume 86, Issue 3, Pages (September 2014)
Cardiac medications and their association with cardiovascular events in incident dialysis patients: Cause or effect?  Areef Ishani, Charles A. Herzog,
Vitamin D levels and patient outcome in chronic kidney disease
Methods for guideline development
Volume 76, Issue 8, Pages (October 2009)
Volume 76, Issue 9, Pages (November 2009)
Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease  C.P. Kovesdy, S. Ahmadzadeh,
Volume 85, Issue 5, Pages (May 2014)
Volume 73, Issue 8, Pages (April 2008)
Volume 80, Issue 12, Pages (December 2011)
Volume 77, Issue 12, Pages (June 2010)
Volume 82, Issue 3, Pages (August 2012)
Volume 81, Issue 7, Pages (April 2012)
Clinical renoprotection trials involving angiotensin II-receptor antagonists and angiotensin-converting-enzyme inhibitors  Barry M. Brenner, Joann Zagrobelny 
Volume 76, Issue 6, Pages (September 2009)
Volume 80, Issue 10, Pages (November 2011)
Michael R. Lattanzio, Matthew R. Weir  Kidney International 
Volume 75, Issue 1, Pages (January 2009)
Areef Ishani, Allan J. Collins, Charles A. Herzog, Robert N. Foley 
Vitamin D deficiency and anemia in early chronic kidney disease
Thiazolidinedione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetes  Steven M. Brunelli, Ravi Thadhani,
Volume 81, Issue 11, Pages (June 2012)
Friends, social networks, and progressive chronic kidney disease
Optimization of pre-ESRD care: The key to improved dialysis outcomes
Volume 78, Issue 5, Pages (September 2010)
Presentation transcript:

Volume 82, Issue 12, Pages 1332-1338 (December 2012) Variability in estimated glomerular filtration rate is an independent risk factor for death among patients with stage 3 chronic kidney disease  Robert M. Perkins, Xiaoqin Tang, Amanda C. Bengier, H. Lester Kirchner, Ion D. Bucaloiu  Kidney International  Volume 82, Issue 12, Pages 1332-1338 (December 2012) DOI: 10.1038/ki.2012.281 Copyright © 2012 International Society of Nephrology Terms and Conditions

Figure 1 Kaplan–Meier curve (time to death) by quartile of estimated glomerular filtration rate variability. Kidney International 2012 82, 1332-1338DOI: (10.1038/ki.2012.281) Copyright © 2012 International Society of Nephrology Terms and Conditions

Figure 2 Multivariate Cox proportional hazard models, estimated glomerular filtration rate (eGFR) variability, and mortality by patient subgroup. Comparisons within each subgroup are between eGFR variability quartiles 4 vs. 1 (Q4 vs. Q1). All models shown are fully adjusted for age, gender, smoking status, hospitalization 6 months before index date, diabetes, hyperlipidemia, coronary artery disease, and peripheral arterial disease; prescription at baseline for beta blocker, HMG CoA reductase inhibitor, nonsteroidal anti-inflammatory, loop or thiazide diuretic, angiotensin-converting enzyme inhibitor, or angiotensin receptor blocker; baseline body mass index and diastolic blood pressure; baseline eGFR, proteinuria, serum albumin, serum high- and low-density lipoprotein; eGFR slope and its second order; and cumulative hospital-associated acute kidney injury during follow-up. We tested the interaction of eGFR variability with diabetic status, tertile of rate of eGFR change, and proteinuria (positive, negative, or test-not-ordered); P-values were 0.95, 0.13, and 0.013, respectively. CL, confidence limits; HR, hazard ratio; LCL, lower confidence limit; UCL, upper confidence limit. Kidney International 2012 82, 1332-1338DOI: (10.1038/ki.2012.281) Copyright © 2012 International Society of Nephrology Terms and Conditions

Figure 3 Dynamic and single-point estimated glomerular filtration rate (eGFR) characteristics of four hypothetical cohort members with stage 3 chronic kidney disease. Serial eGFR values are shown for four hypothetical cohort members, along with derived eGFR slope and derived mean absolute eGFR residual. Patients A–D each have a residual value approximating one of the four variability quartiles in the study. Despite similar baseline eGFR values and similar eGFR slope, eGFR residual may vary substantially among patients with chronic kidney disease. Kidney International 2012 82, 1332-1338DOI: (10.1038/ki.2012.281) Copyright © 2012 International Society of Nephrology Terms and Conditions